Investing

CG Oncology : CGON

CGON

Stock Data

$66.27

$0.47 (0.70%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

CG Oncology, Inc., originally Cold Genesys, Inc., is a pioneering firm in oncolytic immunotherapy, focusing on innovative treatments for bladder cancer. Based in Irvine, California since 2010, the company is dedicated to creating therapies that aim to preserve the bladder in patients with various stages of bladder cancer. Their portfolio includes treatments like BOND-003, CORE-001, and CORE-002, targeting high-risk and muscle invasive bladder cancer, alongside therapies for intermediate-risk patients. CG Oncology is at the forefront of combining their treatments with other cancer therapies to enhance patient outcomes.

All CG Oncology Articles

2 Articles

Trey Thoelcke | Sep 17, 2025 at 8:45 AM EDT

Elon Musk Leads Insider Buying Wave

The highlight of recent insider buying is an enormous purchase of Tesla shares by CEO Elon Musk. But it wasn't…

Trey Thoelcke | Feb 5, 2024 at 12:09 PM EST

Insider Buying at These Biotechs Is Huge

As January wound to a close, beneficial owners, executives, and other insiders took advantage of public offerings of stock at…